You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
宜華健康(000150.SZ):子公司擬170萬元轉讓合肥仁濟腫瘤醫院99%出資份額
格隆匯 11-22 17:40

格隆匯11月22日丨宜華健康(000150.SZ)公吿稱,公司下屬子公司達孜賽勒康醫療投資管理有限公司(簡稱“達孜賽勒康”)持有非營利性醫院合肥仁濟腫瘤醫院(簡稱“合肥仁濟醫院”)99%出資份額,擁有其99%的舉辦者權利。因合肥仁濟醫院被吿知,其所租賃經營辦公場所因不可抗力原因,租賃期限提前到期。如合肥仁濟醫院未能在有效期限內,完成新經營辦公場所的選址和裝修、驗收及系列手續,將面臨醫療許可證到期無法續簽的風險。

公司綜合考慮目前合肥仁濟醫院的經營情況,並結合公司未來戰略部署,若繼續出資合肥仁濟醫院用於經營場所的租賃及裝修,或者終止營業,都將付出巨大成本支出,且合肥仁濟醫院未來長期不能為公司產生正向收益,營利能力重大不確定性。為有效地優化公司的資源配置,公司經審慎研究決定,轉讓所持有的合肥仁濟醫院的出資份額,最小程度降低經營風險、經濟損失。

公司於2021年11月22日召開第八屆董事會第十七次會議,審議通過了《關於公司子公司轉讓合肥仁濟腫瘤醫院99%出資份額的議案》,同意公司下屬子公司達孜賽勒康轉讓其持有的合肥仁濟醫院99%出資份額。該次交易對手方為合肥中誠醫療科技有限公司(簡稱“合肥中誠”)。

達孜賽勒康對合肥仁濟醫院的賬面投資淨值為3915.94萬元,截至該次轉讓前,達孜賽勒康欠付合肥仁濟醫院往來款人民幣2013.78萬元,合肥仁濟醫院欠付達孜賽勒康管理費人民幣34.05萬元。該次轉讓的各方,已同意該項債權債務相互抵消,且合肥中誠、合肥仁濟醫院同意免除達孜賽勒康剩餘應付往來款1979.73萬元的清償責任。最終交易價格,雙方協商確定為170萬元人民幣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account